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altering the thickness of the hyaluronan-sol inner fiber and the quantity of loaded GEM,
and the release can be sustained for as long as 3 weeks. In vitro assays show that
these electrospun fibers effectively inhibit pancreatic cancer cells and promote
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growth of residual tumors than for that of integrated tumors. Furthermore,
immunohistochemistry results show that GEM-loaded fibers promote a higher cell
apoptosis rate than does systemically injected GEM in residual tumors. In addition, the
local delivery of GEM with fibers significantly reduces liver toxicity. In summary, we
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Abstract: The low radical surgery rate of pancreatic cancer leads to increased local 
recurrence and poor prognosis. Gemcitabine (GEM) is the preferred chemotherapeutic for 
pancreatic cancer. However, systemic chemotherapy with GEM has reached a bottleneck due 
to its serious side effects after frequent injections. In this study, GEM is successfully 
enwrapped into electrospun fibers via microsol electrospinning technology to form a stable 
core-shell fibrous structure. The GEM release rate can be adjusted by altering the thickness of 
the hyaluronan-sol inner fiber and the quantity of loaded GEM, and the release can be 
sustained for as long as 3 weeks. In vitro assays show that these electrospun fibers effectively 
inhibit pancreatic cancer cells and promote apoptosis. In vivo studies show that the fibrous 
membranes are better for inhibiting the growth of residual tumors than for that of integrated 
tumors. Furthermore, immunohistochemistry results show that GEM-loaded fibers promote a 
higher cell apoptosis rate than does systemically injected GEM in residual tumors. In addition, 
the local delivery of GEM with fibers significantly reduces liver toxicity. In summary, we 
developed a core-shell electrospun fiber for the controlled and localized delivery of GEM, 









































































Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide;  
The overall 5-year survival rate is less than 5%[1]. Currently, radical surgery is the most 
effective way to cure PDAC. Approximately 20% of PDAC patients can receive surgery when 
diagnosed[2]. However, due to the low rate of negative surgical margins, 80% of patients 
experience cancer recurrence within 2 years, which is a notable challenge facing the prognosis 
of PDAC patients[3].  
Adjuvant chemotherapy after surgery decreases the risk of recurrence and improves 
prognosis in only a small fraction of PDAC patients[4]. The main bottleneck is the many 
disadvantages of anti-tumor drugs, including low bioavailability and strong side effects due to 
their non-specific biodistribution[2, 5]. The compactness of cancerous mesenchymal cells in 
pancreatic cancer also acts as a physiological barrier that prevents drugs from flowing into 
cancerous parenchymal cells, thereby limiting the effective treatment of PDAC[6]. 
Gemcitabine (GEM), a chemotherapeutic, is one of the best drugs for PDAC patients[7]. 
Anemia, leukopenia, neutropenia, thrombocytopenia, and kidney and liver toxicity are the 
most common side effects of GEM[8]. As a water-soluble chemotherapeutic agent, GEM 
primarily relies on intravenous administration, but only a small portion of the drug reaches to 
the pancreatic cancer  through blood circulation[5b, 9]. Since pancreatic cancer has the 
characteristics of wrapped fibrous tissue and sparse blood vessels within the tumor, drug 
delivery through blood circulation has low efficient, greatly reducing the ability of the drug to 
kill pancreatic cancer cells[10]. Therefore, developing a more efficient way to enhance the 
effectiveness of chemotherapeutics and decrease the side effect of drugs to improve the 
prognosis of pancreatic cancer patients after surgery is urgent.  
Polymer-based local drug delivery systems are promising for loading anti-tumor 
therapeutics for cancer treatment[11]. These systems promote the bioavailability of anti-tumor 





































































and decreasing the side effects of drugs[12]. Particularly, biodegradable polymer-based drug-
loaded materials can be used to control and sustain drug release over a long period of time[13]. 
For example, electrospinning is a simple technique for producing drug-loaded polymers[14]. 
Electrospun fibers have a larger surface area for promoting drug loading efficiency and a 
three-dimensional porous structure that can prevent drug diffusion[15]. In addition, electrospun 
fibers are advantageous, because they can be transformed into any shape[16]. Therefore, 
electrospun fibrous membranes can be conveniently implanted into the tumor resection 
margins for the local delivery of chemotherapeutics and, ultimately, patient treatment.  
Water-soluble drugs can be loaded into fibers through emulsion electrospinning, coaxial 
electrospinning and grafting the drugs through surface functionalization of the fibers32. 
Although emulsion electrospinning has the disadvantage of low drug loading efficiency and a 
large amount of surfactant addition[17], surface functionalized electrospun fibers can graft 
water-soluble drugs on the surface of fibers and prevent rapid drug release[18]. Coaxial 
electrospinning can make electrospun fibers with a core-shell structure, and water-soluble 
drugs can be wrapped in the core of electrospun fibers[19]. Another issue with this technique is 
that the water phase core is instable, therefore drug release is too fast[20]. In addition, due to 
the poor stability of the core-shell structure, adjusting the drug release rate through the 
internal structure of the core-shell fibers is difficult. Hydrosol is a water-retaining material 
that fully dissolves water-soluble drugs and creates an interphase to prevent drug diffusion 
into organic solvents, thereby acting as an excellent drug carrier[21]. The combination of 
emulsion electrospinning and hydrosol for loading water-soluble drugs may achieve high drug 
loading capacity and controllable drug release with a sustained release profile.  
The aim of this study is to further explore a safe, efficient way to improve the survival of 
PDAC patients after surgery using as a model drug the water-soluble GEM and electrospun 
fibrous scaffolds comprising poly(L-lactide) (PLA) and hyaluronan (HA, approved by the 





































































microsol electrospinning technology to load GEM and develop a GEM-loaded PLA 
electrospun fibrous membrane, which controls GEM release through changing the thickness 
of the inner-hydrosol in the fiber. The biocompatibility and drug release behavior of the 
material are evaluated in vitro, and the cytotoxicity and ability of this material to inhibit 
pancreatic cancer are investigated in vitro in a nude mouse xenograft tumor and residual 
tumor models. 
 
2. Results  
2.1 Characterization of fibrous scaffolds and GEM Release 
First, we prepared hyaluronic acid hydrosol and used it to dissolve GEM to form GEM-
HA-sol. Next, GEM-HA-sol was dispersed into PLA solution to form the electrospinning 
solution through emulsification during which sol particles were dispersed. Finally, sol-
electrospinning was used to construct the electrospun fibrous membrane with a stable core-
shell fibrous structure and loaded with GEM (Figure 1A). We prepared electrospun fibrous 
membranes containing various amounts of GEM (denoted GEM1@PLA-HA, GEM2@PLA-
HA and GEM3@PLA-HA) with different contents of sol (denoted GEM1@PLA-HA, 
GEM1@PLA-HA2, and GEM1@PLA-HA3). Figure 1B shows the morphology of the 
electrospun fibrous membrane, and no HA-sol particles were observed on the surface of the 
fiber. The diameters of PLA, GEM1@PLA-HA, GEM2@PLA-HA, GEM3@PLA-HA, 
GEM1@PLA-HA2 and GEM1@PLA-HA3 fibers were 1.15±0.38 µm, 1.26±0.35 µm, 
1.32±0.46 µm, 1.41±0.33 µm, 1.30±0.47 µm and 1.21±0.39 µm, respectively, and none of the 
membranes showed significant differences with different quantities of GEM.  
The fibrous morphology was further evaluated with transmission electron microscopy 
(TEM), and a clear core-shell structure was observed for HA-sol-PLA. The inner fibers 
formed by the HA-microgel had diameters of 0.37±0.07 µm, 0.48±0.11 µm, 0.39±0.09 µm, 





































































HA, GEM1@PLA-HA2 and GEM1@PLA-HA3, respectively. Figure 1B shows that the outer 
diameter of GEM@PLA-HA was larger than that of PLA, indicating that GEM-sol loading 
slightly affected the PLA fiber diameter (Table 1). As shown in Table 1, with the same HA-
sol content, increasing the amount of GEM content did not have a clear effect on the core and 
shell diameter of the fiber. Both core and shell diameters decreased with a decrease in HA-sol 
content. Therefore, HA-sol not GEM played a dominant role in affecting the core and shell 
diameter of the fiber.  
The surface wettability of the electrospun membranes was measured by WCA, and the 
water contact angles (WCA) were 128.3±2.7o, 130.4±3.3o, 127.2±3.18° 128.57±3.5°, 
131.7±4.3° and 130.1±4.3° for PLA, GEM1@PLA-HA, PLA-GME2, GEM3@PLA-HA, 
GEM1@PLA-HA2 and GEM1@PLA-HA3, respectively. The wettability of all electrospun 
membranes revealed a hydrophobic surface, and there were no significant differences among 
the different groups. Therefore, the fibrous membranes showed poor water permeability.  
Subsequently, we examined the release behavior of GEM from the fibers containing 
different amounts of GEM and HA-sol (Figure 1C). With the increased amount of GEM in 
HA-sol, the release rate of GEM from the electrospun fibers increased (Figure 1C). With 
increased GEM loading, the fibrous membrane showed an initial burst release of GEM of 
21.4%, 25.7% and 29.8% within 1 day (Figure 1C). GEM3@PLA-HA released GEM over 
more than 2 weeks, whereas GEM2@PLA-HA and GEM1@PLA-HA released GEM for 
longer than 3 weeks.  
In addition, for the same drug loading content, GEM1, the drug release further decreased by 
reducing the amount of HA-sol in the fibers. With more HA-sol content in the fibers, the 
GEM release rate increased (Figure 1C). The initial drug release from GEM1@PLA-HA, 
GEM1@PLA-HA2 and GEM1@PLA-HA3 was 21.4%, 19.7% and 6.8%, respectively, within 
1 day. On the 26th day, the content of GEM released from GEM1@PLA-HA3 was only 2/3 of 





































































molecules are gradually released from the fiber by diffusion[22]. The early burst of drug 
release was mainly caused by the diffusion of the drug out of HA molecules that created pores 
in the core. Based on TEM images, GEM1@PLA-HA3 had a thicker shell than did 
GEM1@PLA-HA (0.97 µm vs 0.89 µm); this difference in shell thickness might account for 
the delay of HA and drug diffusion out of the fibers. This result is in good agreement with the 
findings of a previous study by Wen et al., who showed that increasing the shell thickness can 
delay the drug release rate[23]. Thus, by adjusting the GEM- and HA sol content, it is possible 
to control GEM release in fibers and tailor them to different kind of biomedical applications.  
 
2.2 In vitro compatibility of PLA membrane  
Fibroblast cells plays an important role in the progression of pancreatic cancer. These cells 
promote the proliferation and metastasis of pancreatic cancer cells and can also induce GEM 
resistance in pancreatic cancer. Hence, we investigated whether a PLA-HA electrospun 
membrane would affect fibroblast cells and pancreatic cancer cells[24]. We first performed a 
CCK8 assay to investigate cell growth on PLA or PLA-HA electrospun membranes to 
evaluate whether they were biocompatible. PANC-1 and 3T3 cells (mouse fibroblast cell line) 
were inoculated on PLA or PLA-HA electrospun membranes in 24-well plates, and cell 
proliferation was evaluated on days 1 and 3. Comparing with controls, PANC-1 and 3T3 cells 
grown on electrospun PLA showed no change in cell viability; however, cells grown on HA-
PLA showed slightly higher viability than did those grown on the control and PLA because 
HA promotes the adhesive capacity of cells (Figure 2A). This result indicates that HA-PLA 
and PLA electrospun membranes displayed no cytotoxicity to cells. Furthermore, the adhesive 
morphologies of 3T3 and PANC-1 cells growth on PLA or PLA-HA electrospun membranes 
on days 1 and 3 were detected by phalloidin staining to investigate whether the PLA-HA 
membrane affects fibroblasts or pancreatic cancer cells. We investigated this aspect, because 





































































change from a polygon shape into a shuttle shape, which promotes metastasis[25]. Moreover, 
and the shuttle shape of fibroblasts might affect the growth rate[26]. Figure 2B shows that the 
cell size decreased and the outline of the cells changed when inoculated on PLA or 
electrospun PLA-HA, which might be due to the three-dimensional structure displayed in the 
two-dimensional photo. The morphology of fibroblasts remained in a shuttle shape and 
pancreatic cancer cells remain in a polygonal shape. In addition, no cell morphology change 
was observed between PLA and PLA-HA in scanning electron microscopy (SEM) (Figure 
2C). The above results demonstrate that PLA and PLA-HA electrospun fibrous membranes 
are biocompatible and can be used for biomedical applications.  
  
2.3 GEM-loaded PLA-HA membranes in vitro 
The anti-cancer effect of GEM-loaded PLA-HA membranes in vitro was studied by a 3-
[4, 5-dimethylthiazol-2-yl]-2, 5 diphenyl tetrazolium bromide (MTT) assay. The three GEM-
loaded PLA-HA membranes contained different quantities of GEM. In Figure 1C, GEM 
release experiments showed that GEM3@PLA-HA was loaded with the maximum amount of 
GEM, followed by GEM2@PLA-HA and GEM1@PLA-HA. Figure 3A shows the cell 
viability of BxPC-3 and PANC-1 cells treated with PLA-control (no GEM-loaded PLA 
membranes), GEM1@PLA-HA, GEM2@PLA-HA or GEM3@PLA-HA. Compared with the 
control group, the PLA and PLA-HA groups showed no cytotoxicity when incubated with 
PANC-1 and BxPC-3 cells. For the other groups, GEM3@PLA-HA showed higher anti-
proliferation activity than did GEM2@PLA-HA and GEM1@PLA-HA against PANC-1 and 
BxPC-3 cells (P<0.001), because GEM3@PLA-HA loaded and released more GEM than did 
GEM2@PLA-HA and GEM1@PLA-HA. In addition, the PANC-1 cell viability decreased 
with an increased incubation time with PLA-HA-GEM; cell viability almost decreased to zero 





































































gemcitabine to effectively kill pancreatic cancer cells. Since GEM induces apoptosis in cancer 
cells through interfering with DNA replication[27], we performed an Annexin V/propidium 
iodide (PI) double staining to determine which kind of material possessed the greatest ability 
to induce cell apoptosis in BxPC-3 and PANC-1 cells. GEM3@PLA-HA had the strongest 
effect on apoptosis induction, which was in good agreement with the MTT assay (Figure 3B). 
Thus, cell cytotoxicity was positively associated with the loaded amount of GEM in the fibers 
and the treatment time, and we selected GEM3@PLA-HA for subsequent in vivo studies.  
 
2.4 In vivo anti-integrated tumor capability 
A xenograft tumor model of pancreatic cancer was used to evaluate the anti-tumor ability 
of GEM3@PLA-HA in vivo. We implanted a GEM3@PLA-HA electrospun membrane into 
the tumor surface as depicted in Figure 4A. The tumor volume and tumor weight of mice that 
received GEM3@PLA-HA local chemotherapy were almost the same as those of mice that 
received GEM chemotherapy (GEM group) (Figure 4B-D). Weight change was an easily 
measured indicator of the side effect of chemotherapy. We noticed that the weights of mice in 
the GEM group were significantly lower than those of mice in the PLA-GEM3 group (Figure 
4E). Systemic administration of GEM caused side effects because of the whole biodistribution 
of GEM unlike local chemotherapy with PLA-GEM3, which minimized the side effects of the 
drug, since GEM mainly acted at the tumor site instead of being distributed throughout the 
whole body.  
We also performed immunohistochemical (IHC) staining to evaluate the proliferation 
and apoptosis status in the tumor tissues of the two groups (Figure 4F). The staining levels of 
the proliferation index Ki-67 and the anti-apoptosis index Bcl-2 were similar between the two 
groups, and the pro-apoptosis index cleaved caspase-3 also exhibited the same tendency 





































































GEM3@PLA-HA electrospun membrane was as good as that of systemic chemotherapy with 
GEM, while extensively minimizing the side effects of the drug.   
  
2.5 In vivo anti-residual tumor effect  
Radical surgery for pancreatic cancer is difficult to achieve; therefore, the local tumor 
recurrence rate after surgery remains high, and compared with a integrated tumor, a residual 
tumor is often more aggressive and difficult to treat. In this study, we further investigated the 
anti-residual xenograft tumor capability of GEM3@PLA-HA. The GEM3@PLA-HA 
electrospun membrane (Figure 5A) was implanted into the residual tumor and compared with 
systemic chemotherapy with GEM. Interestingly, the anti-tumor capability of GEM3@PLA-
HA was superior to that of GEM, and compared with the control, GEM also showed an anti-
tumor effect (Figure 5B). As shown in Figure 5C and D, the tumor volume (P = 0.0188) and 
tumor weight (P = 0.0134) of the GEM3@PLA-HA group were significantly lower than those 
of the GEM group and control group. The mouse weight of the GEM3@PLA-HA group was 
higher than that of the GEM group and control group (Figure 6E). Furthermore, we detected 
the expression of Ki-67, Bcl-2 and cleaved caspase3 with IHC (Figure 6F). The proliferation 
index Ki-67 and the anti-apoptosis index Bcl-2 were lower in the GEM3@PLA-HA group, 
and the apoptosis index cleaved caspase3 was higher in the GEM3@PLA-HA group (Figure 
6G). All these results demonstrate that local GEM delivery with PLA-HA was more effective 
than systemic drug delivery for treating residual tumors when tumor integrity was destroyed. 
Thus, the deficiency in the protective membrane of the tumor benefited the GEM delivery 
from the GEM-loaded electrospun membranes.  
 
2.6 Side effect reduction of GEM-loaded electrospun fibers 
Only a small amount of GEM can enter the tumor tissue when systemic chemotherapy is 





































































GEM leads to serious side effects in pancreatic cancer patients, and liver toxicity is 
particularly obvious[28]. Our study found that GEM-loaded electrospun fibrous membranes 
reduce the side effects of GEM on liver toxicity. As shown in Figure 6, nude mice receiving 
systemic chemotherapy with GEM had liver damage and hematoxylin and eosin (HE) staining 
of the liver showed liver cell necrosis, while no necrosis was observed for the mice receiving 
GEM3@PLA-HA localized chemotherapy or saline alone(Figure 6A). We also measured 
blood plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT), which 
reflect the liver function of nude mice treated with GEM or GEM3@PLA-HA. The AST and 
ALT levels of mice in the GEM group were significantly higher than those in the 
GEM3@PLA-HA group (Figure 6B). These results suggest that the localized delivery of 
GEM with PLA-HA electrospun membranes to pancreatic cancer could decrease the toxicity 
of GEM, which is clinically important for the treatment of PDAC.  
 
2.7 Mechanism for drug release and chemotherapy 
Currently, the most effective treatment for pancreatic cancer is surgery, but only 
approximately 20% of pancreatic cancer patients can receive surgery, because most patients 
are in the advanced stage when diagnosed. However, only 20% of these patients can receive 
radical surgery, and the remaining 80% who undergo pancreatic cancer surgery might have 
local tumor cell residue[29]. Systemic chemotherapy with GEM is a way to improve the 
survival of pancreatic cancer patients[28, 30]. Due to its special pathologic characteristics, 
pancreatic cancer has a poor blood supply; pancreatic cancer cells are surrounded by abundant 
fibrous connective tissue that compresses tumor blood vessels and cause chemotherapeutics to 
concentrate; compared with other types of solid tumors, pancreatic tumors exhibit less blood 





































































In view of the above situation, we used GEM-loaded PLA-HA electrospun fibrous 
membranes with a core-shell structure using sol-electrospinning technology to provide 
sustained release of GEM at the site of the tumor. The release time of GEM could be adjusted 
by the thickness of core and sustained over 3 weeks. Localized drug delivery has been proven 
to effectively inhibit the growth of tumors in cervical[12b], colorectal[32], and liver cancers[13b] ; 
it also reduces the side effects of chemotherapeutics.  
As illustrated in Figure 7, one of the physiological features of PDAC is that the tumor is 
tightly packed and surrounded with fibrous tissue, which presents a great challenge for drug 
penetration into tumor [33]. Thus, in the xenograft pancreatic tumor model, GEM@PLA-HA 
did not show better efficiency than systemically administered GEM(Figure 7A). Localized 
delivery of the drug to a particular body compartment, thereby lowering the systemic drug 
level, suggesting that localized delivery drug could penetrate to vessels[34]. However, the 
fibrous tissue in pancreatic cancer not only prevented the gemcitabine released by 
gemcitabine-loaded membranes from penetrating to tumor and tumor vessels, but also 
compressed the tumor vessels which reduced the concentration of gemcitabine. Therefore, 
after surgery, with the loss of tumor integrity, the fibrous tissue around the tumor is also 
destroyed. The destruction of the fibrous matrix in pancreatic cancer could promote GEM 
penetration into the tumor tissue[10b, 35]. Thus, the gemcitabine locally released from GEM-
loaded membranes was more capable of penetrating tumor tissues (Figure 7B). GEM@PLA-
HA was combined with sol-electrospinning technology and a GEM-loaded hyaluronic acid 
hydrogel, which showed significantly better efficicacy in the treatment of residual tumors than 
did systemically administered GEM. In addition, when tumor was completely resected, the 
GEM-loaded membranes could kill the pancreatic cancer cells which might scattered in the 
surgical site. 
PLA-HA electrospun fibers had good biocompatibility, and another great advantage of 





































































minimized the systemic biodistribution of the drug and greatly reduced the spread of GEM to 
healthy tissues, such as the liver. In our study, mouse bodyweight was clearly higher in the 
GEM@PLA-HA group than in the GEM group, indicating the reduced side effects of the drug. 
GEM@PLA-HA also clearly reduced the liver injury and liver toxicity. In addition, it is very 
easy to attach GEM@PLA-HA to the tumor bed after surgery because the shape of the 
electrospun fibrous membrane could be tailored. Therefore, for patients with pancreatic 
cancer after surgery, the membranes could be attached to the local surgical site and continue 
to release GEM to kill possible residual tumor cells and prevent tumor recurrence. However, 
GEM-loaded fibrous membranes as a therapeutic tool for localized treatment of pancreatic 
cancer after surgery also had drawbacks. For example, the membranes must be placed into the 
surgical field only one time, resulting in limited for long-term localized treatment of 
pancreatic cancer after surgery. In addition, this kind of localized treatment could not 
significantly increase the concentration of a chemotherapeutic agent in the blood, thus it 
might not work well for pancreatic cancer cells that might have already metastasized into the 
blood circulation, combined with systemic chemotherapy of GEM might help to resolve the 
deficiency of localized chemotherapy, and they could collaborate to against pancreatic cancer.  
 
3. Conclusions  
GEM was dispersed in hyaluronic acid hydrosol and subsequently enwrapped into PLA-
HA electrospun fibers via sol-electrospinning technology to form stable core-shell fiber 
structures. The GEM loading content can be easily adjusted by dispersing different amounts 
of GEM in HA sol-gel, and the release rate is controlled by the thickness of the sol-gel core in 
the PLA fiber. Sustained GEM release lasted over 3 weeks, which facilitated its in vivo 
application for localized drug delivery. GEM@PLA-HA electrospun fibrous membranes were 





































































to GEM treatment in animal models with an integrated xenograft pancreatic cancer tumor, this 
difference might be due to the fibrous tissue around the tumor limiting GEM penetration into 
tumor tissues when the tumor was integrated. However, compared with intravenously 
administered GEM, the GEM@PLA-HA electrospun fibrous membrane was more efficient 
inhibiting the growth of residual tumors. Furthermore, GEM@PLA-HA significantly reduced 
the adverse side effects of GEM, including reduced liver toxicity. Therefore, this kind of local 
implanted drug-loaded scaffold has potential in the prevention and treatment of tumor 
recurrence after surgery. Overall, in this study, we developed a promising platform of 
GEM@PLA-HA electrospun fibrous membranes for local chemotherapy of pancreatic cancer. 
 
4. Experimental Section  
Materials.  
PLA (Mw= 140 kDa, Mw/Mn = 1.85) was purchased from Jinan Daigang Co. (Jinan, China). 
Fermentation-derived HA (sodium salt, Mw = 0.5 MDa) was purchased from Yuancheng 
Technology Co. (Wuhan, China) and used without further purification. GEM was purchased 
from Eli Lilly and Company (USA). All solvents were purchased from Jiangsu Qiangsheng 
Functional Chemistry Co., Ltd. and used without further purification.  
 
Fabrication and characterization of electrospun fibrous scaffolds.  
HA hydrosols (1 wt-%, obtained by adding 0.1 g HA to 9.9 g distilled water and stirring until 
completely dissolved) were prepared in three groups containing 30, 45 and 60 mg of GEM in 
1 mL HA solution. Drug-loaded HA-sol was added to a solution of dichloromethane (DCM, 
8.0 g) containing 1% sorbitan monooleate (Span-80,with respect to PLA) (Table 1). To 
prepare uniform water-in-oil (W/O) emulsions containing microsol particles, we stirred the 
mixture vigorously for 20 min. Next, 1.0 g PLA and 4.0 g of N,N-Dimethylformamide (DMF) 





































































solution. PLA solution was used as the control and prepared as follows: 1.0 g PLA was added 
to 8.0 g DCM and stirred completely, and then 2.0 g DMF was added to the mixture. The 
electrospinning equipment had a high voltage statitron (Tianjing High Voltage Power Supply 
Co., Tianjing, China) set to 10–25 kV. The electrospinning solution was added by a 5-mL 
syringe attached to a metal needle with a 0.6-mm diameter and was electrospun at the flow 
rate of 0.2 to 6 mL/h controlled by a microinject pump (Lange Medical Instrument Co., 
Baoding, Hebei, China). The GEM-loaded PLA electrospun fibrous membranes were 
obtained through microsol electrospinning technology. PLA solution was used as the control 
and prepared as follows: 1.0 g PLA was added to 8.0 g of DCM and stirred completely, and 
2.0 g of DMF was added to the mixture. All of the fibrous scaffolds were lyophilized 
overnight to remove the solvent and water residue and stored at 4 C in a desiccator until 
further use.    
Fiber morphologies were examined by field-emission scanning electron microscopy 
(FESEM) using a Hitachi 4800 system with an acceleration voltage of 3.0 kV. Before SEM 
observation, the fibers were sputter-coated with platinum. TEM images of an individual 
fiber’s inner structure were obtained by a Hitachi HT7700 instrument at 120kV. The static 
WCA of microfibrous membranes were measured using a contact angle analyzer (DSA25S, 
Data Physics Corporation).  
 
In vitro drug release tests.  
The test specimens (20 × 20 mm, approximately 350 µm thick; total mass = 50 mg) of PLA 
fibrous membranes were immersed in 10 mL phosphate buffered saline (PBS, 154 mM, pH 
7.4). The suspension was placed in a 50 mL centrifugal tube and maintained in a thermostat 
shaker (Thermo, USA) at 37 C with 100 cycles/min. Next, 2.0 mL release buffer was 
removed from the centrifugal tube and 2.0 mL fresh PBS was replaced at different time points. 





































































by high-performance liquid chromatography (HPLC, Waters) with a mobile phase of 0.05 M 
ammonium acetate buffer and methanol (90:10%) at a flow rate of 1 mL/min, a detection 
wavelength of 268 nm, and a column (C18, 250 mm × 4.6 mm for length, 5 µm for filler size) 
temperature of 30 C. Based on the initial weight of GEM incorporated into the electrospun 
fibrous membrane, the percentage of released drug from the membranes was calculated.  
 
Cell culture and reagents.  
Human PDAC cell lines (PANC-1 and BxPC-3) and mouse fibroblast 3T3 cells were 
purchased from the Chinese Academy of Sciences. PANC-1 and 3T3 cells were cultured in 
Dulbecco's Modified Eagle’s Medium (DMEM), and BxPC-3 cells were cultured in Roswell 
Park Memorial Institute-1640 (RPMI-1640) medium. All culture media contained 10% fetal 
bovine serum (Gibco), 100 U/mL penicillin and 100 U/mL streptomycin (Sigma). Cells were 
cultured at 37 C in a humidified atmosphere containing 5% CO2.  
 
Phalloidin staining.  
Approximately 2×104 cells were seeded on PLA membranes in 48-well plates for 1 and 3 
days. For fluorescence microscope observations, cells were washed with PBS, fixed in 4% 
formaldehyde solution for 30 min and washed twice with PBS. Subsequently, the cells were 
incubated with 0.1% Triton X-100 for 5 mins and phalloidin solution (Yearsen, China) for 30 
min, washed twice with PBS, and finally incubated in 4', 6-diamidino-2-phenylindole (DAPI) 
solution for 10 min in the dark.  
 
Cell proliferation.  
Cell viability was evaluated with a cell counting kit (CCK-8, Dojindo, Japan). Fibrous 
materials were cut into the proper size to cover the wells in 24-well plates and placed into the 





































































were decontaminated under ultraviolet (UV) irradiation overnight. Approximately 4×104 3T3 
or PANC-1 cells were seeded on the PLA electrospun membranes in 24-well plates for 
culturing for 1 and 3 days and cells cultured without membranes were used as the control. 
After incubation, the wells were refreshed with new culture medium with 10% CCK8 solution 
and cultured at 37 C for another 2 h to allow the reaction to proceed. Finally, 100 µL reaction 
medium was transferred into 96-well plates for absorbance measurements at a wavelength of 
450 nm with a microplate reader. 
 
Cell viability assay.  
The cytotoxicity of a GEM-loaded electrospun membrane against PANC-1 and BxPC-3 cells 
was assessed by a MTT assay (Yearsen, China). Approximately 4×104 PANC-1 and BxPC-3 
cells were cultured in a 24-well plate with culture medium overnight. Wells were divided into 
the following groups: (1) Control group, cells cultured in 24-well plates; (2) PLA control 
group, 5×5 mm PLA membranes were added in the bottom of the wells; (3) PLA-HA control 
group, 5×5 mm PLA-HA membranes were added; (4) GEM1@PLA-HA group, 5×5 mm 
GEM1@PLA-HA membrane were added; (5) GEM2@PLA-HA, 5×5 mm GEM2@PLA-HA 
membranes were added; and (6) GEM3@PLA-HA, 5×5 mm GEM3@PLA-HA membranes 
were added. All materials were decontaminated under UV irradiation overnight before the 
experiments. After culturing for 3, 5, and 7 days, MTT assays were performed for cell 
viability as measured by a microplate reader (MULTISKAN MK3, Thermo Scientific) at the 
wavelength of 490 nm.  
 
Apoptosis assay.  
PANC-1 and BxPC-3 cell apoptosis induced by GEM-loaded PLA electrospun membranes 
was evaluated by flow cytometry (FCM) with Annexin V-fluorescein isothiocyanate 





































































well plates and cultured overnight, and GEM-loaded PLA electrospun membranes containing 
different amounts of GEM (GEM1@PLA-HA, GEM2@PLA-HA, and GEM3@PLA-HA) or 
PLA electrospun membranes (PLA-control) were placed into culture medium for 3 days of 
cell culture; all materials were cut into 1×1 cm pieces and decontaminated under UV 
irradiation for 24 h. Cells were collected, washed with cold PBS and centrifuged at 1500  g 
for 5 min. Next, the cells were incubated with Annexin V-FITC and PI solution (Yearsen, 
China) for 10 min and analyzed by FCM. 
 
Xenograft tumor model.  
Animal experiments were permitted by the Ethical Review Committee of the Sixth Affiliated 
Hospital of Shanghai Jiaotong University. Six-to-eight-week-old male BALB/c athymic mice 
(nude mice) were purchased from Shanghai Si Lai Ke Laboratory Animal Co., Ltd. China. 
Approximately 1×107 PANC-1 cells were subcutaneously inoculated into the right thigh of 
nude mice (n = 5). After the tumors grew to 70 mm3, the mice were divided into two groups. 
One group received peritoneal administration of GEM (100 mg/kg) and was denoted the GEM 
group. For the other group, a small incision was made on the skin to expose the tumor, and 
GEM3@PLA-HA membranes (cut as 2×2 cm2) were placed on the tumor surface; this group 
was denoted the GEM3@PLA-HA group. Mice were weighed, and the tumor volume was 
calculated by caliper every 3 days as follows: V = 0.5 × (length × width2). After the mice 
were euthanized, tumors were collected for further studies; tumors were embedded in paraffin 
and cut into 5-μm-thick sections for IHC analysis.  
 
Residual tumor model.  
Approximately 1×107 PANC-1 cells were subcutaneously inoculated into the right flank of 
nude mice (n = 5). After the tumor grew to 100 mm3, a small incision was made on the mouse 





































































× 4 mm of tumor tissue remained), as in our previous study 26. Mice were divided into three 
groups, including the control, GEM and GEM3@PLA-HA groups. Mice in the control group 
were intraperitoneally injected with saline; Mice in the GEM3@PLA-HA group were locally 
implanted with GEM3@PLA-HA membrane; The mice in  GEM group were intraperitoneally 
injected with GEM (100 mg/kg) twice a week. Before the materials were implanted, they 
were cut into 2×2 cm in size. Mice were weighed, and tumor volume was calculated as 
follows: V = 0.5 × (length × width2) [36]. After the mice were euthanized, tumors and blood 
were collected for further analysis; tumors were embedded in paraffin and cut into 5-μm-thick 
sections for IHC analysis. Plasma was harvested from blood by centrifugation at 3,000 rpm 
for 10 min. Next, liver function was tested by measuring AST and ALT. 
 
Immunohistochemical (IHC) staining analysis.  
Tumor tissues were fixed in 4% paraformaldehyde, embedded in paraffin, cut into in 5-m-
thick sections, deparaffinized with xylene, gradient-rehydrated with ethanol and subjected to 
antigen-retrieval with citrate buffer at 95 C for 15 min. Sections were later blocked with goat 
serum for 10 min and incubated with primary antibodies (Ki-67, caspase-3 and Bcl-2) for 30 
min at room temperature. Next, the membrane was incubated with a goat anti-rabbit 
secondary antibody conjugated to horse radish peroxidase (HRP) for 10 min at 37 C. The 
targeted marker was detected with 3, 3'-diaminobenzidine (DAB)  over 1−5 min. The nucleus 
was stained with hematoxylin. All staining was observed and photographed using a 
microscope (Nikon ECLIPSE 80i).    
 
IHC quantification.  
IHC staining for Bcl-2 was evaluated on the basis of staining intensity and staining 
proportion; at least five fields of 400× magnification were counted. The staining intensity was 





































































proportion was scored from grades 1−3 (1, <10% of positive cells; 2, 10−49%; 3, >50%)[27]. 
The IHC score was calculated by multiplying the scores of staining intensity by proportion. 
IHC staining for Ki-67 and cleaved caspase3 was evaluated on the basis of the number of 
stained cells. 
Statistical analysis.  
Statistical Product and Service Solutions (SPSS) 18.0 software was applied for all statistical 
analysis. The results are presented as the mean ± standard deviations (SD). For samples that 
were used for MTT analysis, an n=4 or 5 was used, for samples that were used for in vivo 
experiment, an n=5 was applicable. Multiple group comparisons were performed by applying 
one-way ANOVA, and post hoc Bonferroni was performed to test the differences. Two-group 
comparisons were performed by using Student’s t-test. * p-value < 0.05, ** p-value < 0.01 
and *** p-value< 0.001 represented Statistically significant differences 
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Figure 1. (A) Schematic illustration of the process of constructing GEM-loaded PLA 
electrospun fibrous membranes withsol-electrospinning technology. (B) SEM images of PLA 
(a), GEM1@PLA-HA (b), GEM2@PLA-HA (c), GEM3@PLA-HA (d), GEM1@PLA-HA2 
(e), and GEM1@PLA-HA3 (f) fibers (insert pictures are TEM images of the fiber to show the 
core-shell). (C) GEM release profiles of fibers containing different drug content 
(GEM1@PLA-HA, GEM2@PLA-HA and GME3@PLA-HA) and different sol-content 
(GEM1@PLA-HA, GEM1@PLA-HA2 and GEM1@PLA-HA3) (n = 3). Data represent the 
mean±SD.  
 
Figure 2. (A) Cell viability of 3T3 and PANC-1 cells grown on PLA or PLA-HA eletrospun 
membranes for 1 and 3 days (n = 4). (B) Morphology of 3T3 and PANC-1 cells grown on 
PLA or PLA-HA electrospun membranes or culture plates for 1 and 3 days of incubation. Red 
scale bars indicate 100 µm. (C) Morphology of 3T3 and PANC-1 cells grown on PLA or 
PLA-HA electrospun membranes for 3 days were imaged by SEM. Scale bars indicate 50 μm. 
Data represent the mean±SD, and ** indicates p < 0.01. 
 
Figure 3. (A) Cell viability of PANC-1 and BxPC-3 cells treated with GEM-loaded 
electrospun membranes (PLA, PLA-HA, GEM1@PLA-HA, and GEM2@PLA-HA, 
GEM3@PLA-HA) for 3, 5, 7 days (n = 5). (B) Flow cytometry of AnnexinV/PI double 
staining: cell apoptosis of PANC-1 and BxPC-3 cells treated with GEM-loaded electrospun 
membranes (PLA, PLA-HA, GEM1@PLA-HA, GEM2@PLA-HA, and GEM3@PLA-HA) 







































































Figure 4. (A) Schematic illustration of implantation of GEM3@PLA-HA on the tumor of a 
xenograft tumor model of pancreatic cancer for local chemotherapy. (B) Xenograft tumor 
tissues of pancreatic cancer (n = 5). (C) Tumor volume of the GEM3@PLA-HA and GEM 
groups. (D) Tumor weight of the GEM3@PLA-HA and GEM groups. (E) Mouse weight of 
the GEM3@PLA-HA and GEM groups. (F) IHC staining of Bcl-2, Cleaved-caspase-3 and 
Ki-67. Black scale bars indicate 200 μm. (G) Semi-quantification of Bcl-2, Cleaved-caspase-3 
and Ki-67. Data represent the mean ± SD. * indicates P < 0.05. 
 
Figure 5. (A) Schematic illustration of implantation of GEM3@PLA-HA on the residual 
tumor of a xenograft residual tumormodel for local chemotherapy. (B) Xenograft residual 
tumor of pancreatic cancer (n = 5). (C) Tumor weight of the control, GEM and GEM3@PLA-
HAGEM groups. (D) Tumor volume of the control, GEM and GEM3@PLA-HAGEM groups. 
(E) Mice weight of the control, GEM and GEM3@PLA-HAGEM groups. (F) IHC staining of 
Bcl-2, Cleaved-caspase-3 and Ki-67. Black scale bars indicate 200 μm. (G) Semi-
quantification of Bcl-2, Cleaved-caspase-3 and Ki-67. Data represents mean ± SD. *** 
indicates P < 0.001, ** indicates P < 0.01. 
 
Figure 6. (A) HE staining of the liver after treatment with GEM3@PLA-HA and GEM. 
Black arrows showed the necrosis of liver cells. Black scale bars indicate 200 µm. (B) AST 
and ALT levels of mice treated with GEM3@PLA-HA or GEM. The control group included 
normal nude mice without tumors (n = 5). Data represent the mean ± SD. ** indicates P < 
0.01 and *** indicates P < 0.001. 
 
Figure 7. Schematic illustration of the GEM-loaded PLA eletrospun membrane on pancreatic 
cancer for local chemotherapy. (A) Before surgery, tumor integrity is maintained, and the 





































































surgery, when tumor is incompeletly resected, tumor integrity is destroyed, and the fibrous 
tissue around the tumor is also destroyed, therefore GEM released from the GEM-loaded PLA 
electrospun fibrous membranes can easily penetrate tumor tissues. (C) After surgery, when 
tumor is compeletly resected, and GEM released from the GEM-loaded PLA electrospun 
fibrous membranes can prevent the local tumor recurrence by killing the pancreatic cancer 








































































Figure 1. (A) Schematic illustration of the process of constructing GEM-loaded PLA 
electrospun fibrous membranes with sol-electrospinning technology. (B) SEM images of PLA 
(a), GEM1@PLA-HA (b), GEM2@PLA-HA (c), GEM3@PLA-HA (d), GEM1@PLA-HA2 
(e), and GEM1@PLA-HA3 (f) fibers (insert pictures are TEM images of the fiber to show the 
core-shell). (C) GEM release profiles of fibers containing different drug content 





































































(GEM1@PLA-HA, GEM1@PLA-HA2 and GEM1@PLA-HA3) (n = 3). Data represent the 








































































Figure 2. (A) Cell viability of 3T3 and PANC-1 cells grown on PLA or PLA-HA eletrospun 
membranes for 1 and 3 days (n = 4) (B) Morphology of 3T3 and PANC-1 cells grown on PLA 





































































bars indicate 100 µm. (C) Morphology of 3T3 and PANC-1 cells grown on PLA or PLA-HA 
electrospun membranes for 3 days were imaged by SEM. Scale bars indicate 50 μm. Data 







































































Figure 3. (A) Cell viability of PANC-1 and BxPC-3 cells treated with GEM-loaded 
electrospun membranes (PLA, PLA-HA, GEM1@PLA-HA, and GEM2@PLA-HA, 
GEM3@PLA-HA) for 3, 5, 7 days (n = 5). (B) Flow cytometry of AnnexinV/PI double 
staining: cell apoptosis of PANC-1 and BxPC-3 cells treated with GEM-loaded electrospun 
membranes (PLA, PLA-HA, GEM1@PLA-HA, GEM2@PLA-HA, and GEM3@PLA-HA) 







































































Figure 4. (A) Schematic illustration of implantation of GEM3@PLA-HA on the tumor of a 
xenograft tumor model of pancreatic cancer for local chemotherapy. (B) Xenograft tumor 
tissues of pancreatic cancer (n = 5). (C) Tumor volume of the GEM3@PLA-HA and GEM 
groups. (D) Tumor weight of the GEM3@PLA-HA and GEM groups. (E) Mice weight of the 





































































Bcl-2, Cleaved-caspase-3 and Ki-67. (G) Semi-quantification of Bcl-2, Cleaved-caspase-3 







































































Figure 5. (A) Schematic illustration of implantation of GEM3@PLA-HA on the residual 
tumor of a xenograft residual tumor model for local chemotherapy. (B) Xenograft residual 
tumor of pancreatic cancer (n = 5). (C) Tumor weight of the control, GEM and GEM3@PLA-
HAGEM groups. (D) Tumor volume of the control, GEM and GEM3@PLA-HAGEM groups. 
(E) Mice weight of the control, GEM and GEM3@PLA-HAGEM groups. (F) IHC staining of 





































































quantification of Bcl-2, Cleaved-caspase-3 and Ki-67. Data represent the mean ± SD. *** 







































































Figure 6. (A) HE staining of the liver after treatment with GEM3@PLA-HA and GEM. 
Black arrows showed the necrosis of liver cells. Black scale bars indicate 200 µm. (B) AST 
and ALT levels of mice treated with GEM3@PLA-HA or GEM. The control group included 
normal nude mice without tumors (n = 5). Data represent the mean ± SD. ** indicates P < 










































































Figure 7. Schematic illustration of the GEM-loaded PLA eletrospun membrane on pancreatic 
cancer for local chemotherapy. (A) Before surgery, tumor integrity is maintained, and the 
fibrous tissue around the tumor could prevents GEM from penetrating tumor tissues. (B) After 
surgery, when tumor is incompeletly resected, tumor integrity is destroyed, and the fibrous 
tissue around the tumor is also destroyed, therefore GEM released from the GEM-loaded PLA 
electrospun fibrous membranes can easily penetrate tumor tissues. (C) After surgery, when 
tumor is completely resected, and GEM released from the GEM-loaded PLA electrospun 
fibrous membranes can prevent the local tumor recurrence by killing the pancreatic cancer 





































































































GEM2@PLA-HA 1 400 15 1.32±0.46 0.48±0.11 
GEM3@PLA-HA 1 400 20 1.41±0.33 0.39±0.09 
GEM1@PLA-
HA2 
1 200 10 1.30±0.47 0.30±0.08 
GEM1@PLA-
HA3 














































































A typical water-soluble drug, GEM is successfully enwrapped into electrospun fibers via 
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